{"id":6682,"date":"2026-03-22T14:25:21","date_gmt":"2026-03-22T20:25:21","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=6682"},"modified":"2026-03-22T16:26:47","modified_gmt":"2026-03-22T22:26:47","slug":"idefirix-pdufa-date-and-the-ides-of-march","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2026\/03\/22\/6682\/idefirix-pdufa-date-and-the-ides-of-march\/","title":{"rendered":"Idefirix PDUFA Date and the IdeS of March"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

The pivotal ConfIdeS study has finished enrollment and is now with the FDA.  IdeS is imlifidase, with the brand name Idefirix.  It has been conditionally approved by EMA and is on the market in Europe since 2020. <\/p>\n\n\n\n

Idefirix is a niche product, an orphan drug.  It is a cysteine protease that cleaves IgGs of all classes, and it does so very effectively and quickly. It destroys IgG autoantibodies within a few hours. These antibodies would otherwise prevent organ transplantation for recipients who became highly sensitized to HLA antigens due to prior pregnancies, transfusions or transplantation.  In other words, it makes transplantation of organs possible without the risk of a hyperacute rejection, even in patients with incredibly high cPRA scores which is an indicator of crossmatch incompatibility.<\/p>\n\n\n\n

The US ConfideS study enrolled patients who are highly sensitized, those with a cPRA \u226599.9%.  \u2018Highly sensitized\u2019 is a misnomer in this case: this entry criterium is so strict that it selects only for super-ultra hyper-extra sensitized patients. <\/p>\n\n\n\n

It took Hansa approx. 2 \u00bd years to enroll 64 patients in the ConfIdeS study<\/em><\/p><\/blockquote><\/figure>\n\n\n\n

Finding such patients must have been incredibly difficult. For them, transplantation is a race against the clock. Timely desensitization is nearly impossible. Existing desensitization programs based on plasma exchange just don\u2019t work nearly as well and as fast as idefirix and right now there is no alternative Therefore, a true control arm does not exist. That’s why the ConfideS protocol reads more like an artificial construct. It makes all kinds of allowances for an alternative treatment for hypersensitized patients when there is no idefirix-like agent available.  <\/p>\n\n\n\n

Seven years after the EMA, FDA will get to review the pivotal Phase 3 ConfIdeS trial, plus an assortment of other study data which represent the uncontrolled experience with Idefirix<\/p><\/blockquote><\/figure>\n\n\n\n

While our last blog dealt with FDA \u2018flexibility\u2019, this blog is all about FDA response to a novel break-through therapeutic.  Of course, it might be a lot easier for the Agency to review and approve yet another run-of-the mill PD-1 or JAK inhibitor.<\/p>\n\n\n\n

There is a reason why the enthusiasm for idefirix is a bit subdued.  Idefirix is not a panacea for the niche it is addressing, the highly sensitized ESRD patients.  Elimination of IgGs is temporary and rather short-lived, just long enough to allow transplantation and provide protection of the organ in the immediate post-transplant period.  As the drug effect wears off, IgGs return and so do specific autoantibodies against DSA and anti-drug antibodies (ADA).  Given the half-life for IgG of approx. 21 days, humoral immunity will fully return within 1-2 months after transplant.  And here lies the problem.<\/p>\n\n\n\n

Ideally, one would like to dose idefirix repeatedly titrating its effect over a longer time post-transplant, like other desensitization protocols for CMI suppression.  Regrettably, idefirix is a foreign protein and highly immunogenic.  There is a significant risk of an anamnestic response on repeat dosing, even with premedication.  AMR occurs rather early, in 28% of patients within 1 month of transplant[1]<\/a>. <\/p>\n\n\n\n

It seems that idefirix cannot be made less immunogenic.  We don\u2019t know whether Hansa pursued other ways of reducing ADA as has been done for uricase inhibitors, using a PEGylation approach or co-administration \/ premedication with methotrexate or sirolimus as done with pegloticase, a treatment for hyperuricemia.<\/p>\n\n\n\n

Still, in the absence of a better drug, idefirix is a game changer.  There is really no drug in sight that could compete with idefirix making transplantation possible. <\/p>\n\n\n\n

EMA recognized that dilemma and approved it in Europe for patients who are not candidates for transplant with a very high cPRA score which makes finding a suitable donor next to impossible.  EMA felt that the benefits for these patients outweigh the risks.<\/p>\n\n\n\n

As mentioned earlier, the company has now submitted its dossier to the FDA, and a PDUFA date was set for Nov 2026.  This amounts to a 10-month standard review.  Why so late?  Like Hansa, we would have expected 6-month Priority review given the unmet medical need.  After all, idefirix is a BTD drug for a very small group of patients who have run out of options.  The ConfIdeS Phase 3 study was conducted at 25 US transplant centers; the list of investigators reads like the Who-Is-Who of kidney transplant gurus.  It should have met FDA expectations and led to fast-tracking.<\/p>\n\n\n\n

We know the Agency has all kinds of ways to accelerate reviews.  In this case the data package is relatively small, a single Phase 3 pivotal trial.  Hence, this should not be a colossal task for a Medical Reviewer.<\/p>\n\n\n\n

We hope that FDA and the company explore options like conditional approval and faster review as is now possible in select cases.  The CNPV program comes to mind which is still a pilot.  See table below for review timelines.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n
\n\n\n\n

Hansa is developing an improved version of idefirix.  HNSA-5487, another biological, has already finished Phase 1 testing reportedly with good results (NICE-1 trial) .  However, information is still scant as publications are missing.  Our information is solely based on Hansa press releases. <\/p>\n\n\n\n

HNSA-5487 has a fast onset of action just like idefirix, but the suppression of S-IgG by >75% still only lasts for ~10 days.  Development of ADAs seems less of an issue, making repeat dosing potentially feasible.  We have to take their word for it, but this would be a substantial improvement.<\/p>\n\n\n

\n
\"\"<\/a>
Figure 1:  HNSA-5487 S-IgG lowering – Dose response.  Ref. 1<\/figcaption><\/figure>\n<\/div>\n\n\n

<\/p>\n\n\n\n

Surprisingly, HNSA-5487 is not being developed for the idefirix indication (ie, enabling transplant in the highly sensitized) but for neurologic autoimmune diseases like gMG and NMO.  In these indications it has to compete against FcRn inhibitors and other biologicals already on the market.<\/p>\n\n\n\n

FcRn inhibitors have a MoA quite different from idefirix: They decrease the recycling of IgGs including autoantibodies.  However, onset of action is rather slow and IgG levels only drop by approx. 55-65% at best.  Thus, IgG lowering is insufficient given the short time window available for transplantation (Fig. 2).  However, in combination and as a follow-up to idefirix they could be used, at least conceptually. <\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Several mAbs are routinely used after transplant and all need dose-adjustment when co-administered with idefirix, HNSA-5487 or an FcRn inhibitor.  Such polypharmacy becomes complicated; it requires orchestration by a dedicated team of experts at specialized centers.  We trust it can be done!<\/p>\n\n\n\n

\n\n\n\n

ABBREVIATIONS<\/strong><\/p>\n\n\n\n

ADA           anti-drug antibody
AMR           antibody-mediated rejection
BTD           breakthrough designation
CNPV          Commissioner's National Priority Voucher
cPRA          calculated panel reactive antibodies
DSA           donor specific antibodies
ESRD          end-stage renal disease
FcRn          Fc receptor neonatal
gMG           generalized myasthenia gravis
MOGAD         Myelin Oligodendrocyte Glycoprotein Antibody Disease
NMO           neuromyelitis optica
PDUFA         Prescription Drug User Fee<\/pre>\n\n\n\n
\n\n\n\n
PUBLICATIONS<\/strong>
[1]<\/a> Kjellman C. Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. Am J Transplantation 21: 3907, 2021
[2]<\/a> Tulstrup S.  HNSA-5487 demonstrates very rapid and highly robust IgG reduction and clear redosing potential in Phase 1 FIH trial.  20241007_HNSA-5487_12MonthAnalysis_Presentation.pdf<\/a><\/p>\n\n\n\n
Hansa PR March 3, 2026. <\/a>PDUFA Action Date for Hansa Biopharma\u2019s Imlifidase BLA Set for December 19, 2026 | Hansa Biopharma<\/a>  (accessed 3\/22\/2026)<\/p>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
The pivotal ConfIdeS study has finished enrollment and is now with the FDA.  IdeS is imlifidase, with the brand name Idefirix.  It has been conditionally approved by EMA and is on the market in Europe since 2020.  Idefirix is a niche product, an orphan drug.  It is a cysteine protease Continue reading   Idefirix PDUFA Date and the IdeS of March<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":6690,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[3,18],"tags":[2453,1271,2617,2619,2612,2448,448,2440,2296,5,302,2613,2449,1583,2454,2614,2441,2442,2624,2621,1397,2622,2623,2615,2616,361,2207,2206,446,2618,2620],"class_list":["post-6682","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-the_news","category-the_viewpoint","tag-ada","tag-allphase-pharma-consulting","tag-anti-drug-antibody","tag-breakthrough-designation","tag-confides","tag-cpra","tag-cyclosporine","tag-esrd","tag-fcrn","tag-fda","tag-gbs","tag-guillain-barre-syndrome","tag-hansa-biopharma","tag-harald-reinhart","tag-highly-sensitized","tag-hnsa-5487","tag-idefirix","tag-ides","tag-krystexxa","tag-mogad","tag-mycophenylate","tag-nmo","tag-pegloticase","tag-plasma-exchange","tag-premedication","tag-priority-review","tag-rituxan","tag-rituximab","tag-sirolimus","tag-voucher-program","tag-xvm"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/Hansa-slider.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-1JM","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":5442,"url":"https:\/\/allphasepharma.com\/dir\/2025\/09\/26\/5442\/hansa-where-is-the-beef\/","url_meta":{"origin":6682,"position":0},"title":"HANSA, Where is the Beef?","author":"Harald","date":"September 26, 2025","format":false,"excerpt":"Hansa is a small Swedish company with a unique product, a protease from Strep. pyogenes that cleaves IgG called Imlifidase, Idefirix or IdeS for short.\u00a0They steered IdeS through a difficult early development, obtained approval for their drug in many EU countries for 'desensitisation treatment of highly sensitised adult kidney transplant\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/09\/Hansa-SLIDER2.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/09\/Hansa-SLIDER2.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/09\/Hansa-SLIDER2.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":2862,"url":"https:\/\/allphasepharma.com\/dir\/2016\/11\/07\/2862\/profiling-solithromycin-fda-amdac-on-solithera\/","url_meta":{"origin":6682,"position":1},"title":"Profiling Solithromycin: FDA AMDAC on Solithera","author":"Harald","date":"November 7, 2016","format":false,"excerpt":"Police profiling based on race, sex or gender is a highly controversial practice. FDA doing the same, not so much. Profiling based on similarities to other drugs in the same category is nothing new. Class labeling can be expected for the next new B-lactam or quinolone regardless of whether during\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"solithro-pipe-magritte","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Solithro-Pipe-Magritte.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Solithro-Pipe-Magritte.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Solithro-Pipe-Magritte.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2998,"url":"https:\/\/allphasepharma.com\/dir\/2017\/01\/12\/2998\/omissions-commissions-errors-blunders-solithromycin\/","url_meta":{"origin":6682,"position":2},"title":"Omissions \u2013 Commissions \u2013 Errors \u2013 Blunders – Solithromycin","author":"Harald","date":"January 12, 2017","format":false,"excerpt":"Cempra received a complete response letter (CRL) as a X-mas present from FDA, and the news was pretty bad for company investors. Bad, but not totally unexpected after the AMDAC meeting last November, which taught us a few new things about the drug. It also highlighted how strategic missteps can\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Solithro-Ketek-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Solithro-Ketek-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Solithro-Ketek-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1915,"url":"https:\/\/allphasepharma.com\/dir\/2015\/09\/07\/1915\/dalbavancin-approval-issues-a-case-of-much-ado-about-nothing\/","url_meta":{"origin":6682,"position":3},"title":"Dalbavancin Approval Issues: A Case of Much Ado About Nothing","author":"Harald","date":"September 7, 2015","format":false,"excerpt":"Dalbavancin has changed hands a few times in its development history, moving\u00a0from Lilly to Vicuron, then Pfizer and ultimately Durata. The original NDA for dalbavancin was submitted to FDA on Dec. 21, 2004.\u00a0 Pfizer acquired dalbavancin\u00a0as a \u201cPhase 3 completed\u201d drug ready for world-wide marketing on June 15, 2005. The\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"Dalbavancin slider copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/Dalbavancin-slider-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/Dalbavancin-slider-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/Dalbavancin-slider-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2830,"url":"https:\/\/allphasepharma.com\/dir\/2016\/10\/27\/2830\/solithromycin-solitaire-iv-so-so-results-for-a-so-so-drug\/","url_meta":{"origin":6682,"position":4},"title":"Solithromycin SOLITAIRE-IV: So-So Results for a So-So Drug","author":"Harald","date":"October 27, 2016","format":false,"excerpt":"Just before the November 4th AMDAC on solithromycin, we are being treated to a very fine piece of study write-up. Of course, we are speaking of the File paper on the SOLITAIRE-IV trial, and what a fine piece of crafty penmanship it is, if you haven\u2019t noticed. Just as a\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"soli-iv-newer","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/SOLI-IV-newer.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/SOLI-IV-newer.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/SOLI-IV-newer.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":4303,"url":"https:\/\/allphasepharma.com\/dir\/2025\/05\/05\/4303\/sulopenem-uuti-does-it-suffice\/","url_meta":{"origin":6682,"position":5},"title":"Sulopenem uUTI – Does It Suffice?","author":"Harald","date":"May 5, 2025","format":false,"excerpt":"Sulopenem \/ ORLYNVAH approved for uUTI When Iterum, a Pfizer spin-off of sorts, took over sulopenem development in 2015, there was still hope for approvals of this drug in multiple indications such as uUTI, cUTI, cIAI and even CABP.\u00a0 Ten years later and after an FDA rejection CRL in 2021,\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/Sulopenem-in-uUTI-SLIDER.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/Sulopenem-in-uUTI-SLIDER.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/Sulopenem-in-uUTI-SLIDER.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/6682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=6682"}],"version-history":[{"count":13,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/6682\/revisions"}],"predecessor-version":[{"id":6713,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/6682\/revisions\/6713"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/6690"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=6682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=6682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=6682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}